Besides the specific impact to the personal well being of many woman from particular side effects like alopecia (which is absent from MS but present for paclitaxel as described by O'Mally), the OS benefit from MS in FR-alpha high patients may very well be directly related to its much better tolerability than paclitaxel. Patients can be on the medication for longer, possibly leading to better outcomes than a less tolerable therapy which gets discontinued earlier.
We keep flying under the radar, but as the recent price action from IMMU suggests, we may be just a few key events away from becoming a biotech darling.